Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 9/20 | 0.41 |
| ▸ | CSF1R | P07333 | 6/20 | 0.41 |
| ▸ | KIT | P10721 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.39 |
| ▸ | CLK3 | P49761 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24976584 | 0.93 | FLT3 (0.47) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24975663 | 0.90 | FLT3 (0.62) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24231304 | 0.89 | FLT3 (0.62) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL25989702 | 0.89 | FLT3 (0.62) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24975661 | 0.87 | FLT3 (0.50) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24231493 | 0.86 | FLT3 (0.52) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24975662 | 0.85 | FLT3 (0.47) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL24975668 | 0.85 | FLT3 (0.49) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL31557797 | 0.85 | FLT3 (0.47) | FLT3KDRCSF1RKITKCNH2 | |
| SCHEMBL10239075 | 0.84 | FLT3 (0.59) | FLT3KDRDYRK1ACLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023009833-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | FLT3 1/4885KDR 737/4885CSF1R 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.